Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD19 t-haNK cells |
Synonyms | |
Therapy Description |
CD19t-haNK cells are activated NK cells engineered to express a high affinity Fc receptor and co-express a chimeric antigen receptor targeting CD19, which potentially induce antitumor activity (PMID: 35400595). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD19 t-haNK cells | CD19 Immune Cell Therapy 62 | CD19 t-haNK cells are activated natural killer (NK) cells engineered to express a high affinity Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which potentially induce tumor cell killing (PMID: 35400595). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|